Arriving in the landscape of obesity therapy, retatrutide represents a different approach. Beyond many available medications, retatrutide operates as a twin agonist, concurrently engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. The dual stimulation fosters various beneficial effects, including